Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive immunotherapy with donor lymphocyte transfusions

H J Kolb1, E Holler

  • 1Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany.

Current Opinion in Oncology
|March 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma.

Journal of oncology research and therapy·2025
Same author

Retrospective genome-oriented analysis reveals low transmission rate of multidrug-resistant Pseudomonas aeruginosa from contaminated toilets at a bone marrow transplant unit.

The Journal of hospital infection·2024
Same author

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT.

Blood·2022
Same author

[Intensive care support of patients after stem cell transplantation].

Intensivmedizin + Notfallmedizin : Organ der Deutschen und der Osterreichischen Gesellschaft fur internistische Intensivmedizin, der Sektion Neurologie der DGIM und der Sektion Intensivmedizin im Berufsverband Deutscher Internisten e.V·2020
Same author

Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease.

Science (New York, N.Y.)·2019
Same author

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.

Annals of hematology·2019

Adoptive immunotherapy using donor lymphocytes shows promise for treating leukemia post-transplant. While effective for certain leukemias, managing graft-versus-host disease and myelosuppression remains key for successful treatment.

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Adoptive immunotherapy involves transferring immune cells to combat diseases like leukemia and cancer.
  • Donor lymphocyte infusions (DLIs) have shown significant success in treating recurrent leukemia after allogeneic bone marrow transplantation.
  • Chimerism and donor tolerance are crucial for enabling DLI-based adoptive immunotherapy.

Purpose of the Study:

  • To review the efficacy and challenges of adoptive immunotherapy, particularly donor lymphocyte transfusions, in treating various cancers.
  • To explore the mechanisms behind the graft-versus-leukemia effect and its impact on chimerism.
  • To discuss strategies for mitigating major complications like graft-versus-host disease and myelosuppression.

Main Methods:

  • Review of existing literature on adoptive immunotherapy and donor lymphocyte transfusions in animal models and human patients.

Related Experiment Videos

  • Analysis of treatment outcomes for different hematological malignancies and solid tumors.
  • Examination of methods to manage adverse effects, including cell depletion and dose titration.

    • Main Results:

    • DLIs are highly effective in treating chronic myelogenous leukemia and show efficacy in acute myeloid leukemia, myelodysplastic syndrome, and myeloma.
    • Responses are less common in acute lymphoblastic leukemia and lymphoma, with limited success in solid tumors like breast cancer.
    • Graft-versus-host disease and myelosuppression are significant complications, but can be managed through cell manipulation and marrow transfusion.

    Conclusions:

    • Adoptive immunotherapy with donor lymphocytes is a viable treatment for post-transplant leukemia, especially CML.
    • Further research is needed to optimize DLI protocols, manage side effects, and explore novel strategies involving cytokines and T-cell activation.